Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland.
OBJECTIVE
To ascertain the age and gender distribution of patients receiving anticoagulant (AC) treatment with warfarin, and to establish the prevalence of AC treatment and its indications among the Finnish population.


METHODS
A cross-sectional study in which the patients were identified from the patient records of health centres.


METHODS
Primary health care in the Hospital District of South Ostrobothnia in Finland.


METHODS
Those inhabitants of 15 municipalities in the study area who received AC treatment with warfarin on 1 April 2004. The total number of inhabitants was 132 621 at the end of 2003.


METHODS
Patient age and gender distributions, the prevalence of AC treatment in the study area, and indications for AC treatment.


RESULTS
Altogether 2389 patients were identified, 51.4% of them men. The mean age of the patients was 72.4 years. The prevalence of AC treatment was 1.8%; when age-adjusted to match the Finnish population it was 1.64%. The proportion of men receiving AC treatment was higher than that of women in all age groups. Atrial fibrillation (AF) was the most common main (60.2%) and second (7.2%) indication for AC treatment.


CONCLUSIONS
Compared with Finnish figures 12 years earlier the prevalence of AC treatment has more than doubled, and the proportion of AF among indications has increased from 47% to 67%. New current care guidelines on AF and the increasing proportion of the elderly among the population are probable explanations.
Virjo
Irma
I
Department of General Practice, University of Tampere, Hospital District of South Ostrobothnia, Finland. Irma.virjo@uta.fi
Mäkelä
Kari
K
Aho
Juhani
J
Kalliola
Pentti
P
Kurunmäki
Harri
H
Uusitalo
Leena
L
Valli
Markku
M
Ylinen
Suvi
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005194:Family Practice; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin
BMC Fam Pract. 2009 Oct 30;10:70
19878542
Int J Cardiol. 2005 Mar 10;99(1):37-45
15721497
Cardiovasc Drugs Ther. 2005 Mar;19(2):149-51
16025234
Scand J Prim Health Care. 2007 Jun;25(2):123-8
17497491
Scand J Prim Health Care. 1998 Sep;16(3):183-7
9800233
Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7
19185784
Scand J Prim Health Care. 1996 Sep;14(3):165-70
8885029
Fam Pract. 2004 Dec;21(6):612-6
15465879
N Engl J Med. 2009 Sep 17;361(12):1139-51
19717844
Scand J Prim Health Care. 1999 Mar;17(1):59-63
10229996
Chest. 2008 Jun;133(6 Suppl):234S-256S
18574267
BMC Clin Pharmacol. 2004 Feb 09;4:1
15028124
Scand J Prim Health Care. 2002 Jun;20(2):123-5
12184712
Circulation. 2006 Jul 11;114(2):119-25
16818816
Circulation. 2003 Apr 1;107(12):1692-711
12668507